Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2009 - 2026)

Alnylam Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 65.9% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$335.6 million (down 207.78% YoY) and the FY2025 annual result came in at -$305.2 million, down 203.75% from the prior year.
• Cash from Financing Activities was $15.7 million for Q1 2026 at Alnylam Pharmaceuticals, down from $45.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $297.0 million in Q3 2022 and bottomed at -$448.3 million in Q3 2025.
• A 5-year average of $35.4 million and a median of $45.3 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 210.08% — and 2025, when it slumped 536.33%.
• Alnylam Pharmaceuticals' Cash from Financing Activities stood at $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then dropped by 20.98% to $31.0 million in 2024, then surged by 46.2% to $45.3 million in 2025, then sank by 65.32% to $15.7 million in 2026.
• Business Quant data shows ALNY's Cash from Financing Activities at $15.7 million in Q1 2026, $45.3 million in Q4 2025, and -$448.3 million in Q3 2025.